and Oncology. In October 2013, AstraZeneca announced it would acquire biotech oncology company Spirogen for around US$440 million.

2014

On 19 May 2014, AstraZeneca rejected a "final offer" from Pfizer of £55 per share, which valued the company at £69.4billion (US$117billion). The companies had been meeting since January 2014. If the takeover had proceeded, Pfizer would have become the world's biggest drug maker. The transaction would also have been the biggest foreign takeover of a British company.

1.Previous
3.Next